Pyrrolo[2,1-b][1,3]oxazepine-7-carboxamide, octahydro-8,8-dimethyl-4-[[(2S)-2-(methylamino)-1-oxopropyl]amino]-5-oxo-N-[(1R)-1,2,3,4-tetrahydro-1-naphthalenyl]-, (4S,7S,9aS)- Suppliers list
|
Company Name: |
TargetMol Chemicals Inc.
|
Tel: |
15002134094 |
Email: |
marketing@targetmol.cn |
Products Intro: |
Product Name:SBP-0636457 CAS:1422180-49-1 Package:25mg/RMB 15000
|
|
| Pyrrolo[2,1-b][1,3]oxazepine-7-carboxamide, octahydro-8,8-dimethyl-4-[[(2S)-2-(methylamino)-1-oxopropyl]amino]-5-oxo-N-[(1R)-1,2,3,4-tetrahydro-1-naphthalenyl]-, (4S,7S,9aS)- Basic information |
Product Name: | Pyrrolo[2,1-b][1,3]oxazepine-7-carboxamide, octahydro-8,8-dimethyl-4-[[(2S)-2-(methylamino)-1-oxopropyl]amino]-5-oxo-N-[(1R)-1,2,3,4-tetrahydro-1-naphthalenyl]-, (4S,7S,9aS)- | Synonyms: | Pyrrolo[2,1-b][1,3]oxazepine-7-carboxamide, octahydro-8,8-dimethyl-4-[[(2S)-2-(methylamino)-1-oxopropyl]amino]-5-oxo-N-[(1R)-1,2,3,4-tetrahydro-1-naphthalenyl]-, (4S,7S,9aS)-;SB1-0636457;SBI-0636457;SBP-0636457 | CAS: | 1422180-49-1 | MF: | C25H36N4O4 | MW: | 456.58 | EINECS: | | Product Categories: | | Mol File: | 1422180-49-1.mol | |
| Pyrrolo[2,1-b][1,3]oxazepine-7-carboxamide, octahydro-8,8-dimethyl-4-[[(2S)-2-(methylamino)-1-oxopropyl]amino]-5-oxo-N-[(1R)-1,2,3,4-tetrahydro-1-naphthalenyl]-, (4S,7S,9aS)- Chemical Properties |
Boiling point | 733.0±60.0 °C(Predicted) | density | 1.22±0.1 g/cm3(Predicted) | storage temp. | 4°C, stored under nitrogen | form | Solid | pka | 13.92±0.60(Predicted) | color | Off-white to yellow |
| Pyrrolo[2,1-b][1,3]oxazepine-7-carboxamide, octahydro-8,8-dimethyl-4-[[(2S)-2-(methylamino)-1-oxopropyl]amino]-5-oxo-N-[(1R)-1,2,3,4-tetrahydro-1-naphthalenyl]-, (4S,7S,9aS)- Usage And Synthesis |
Biological Activity | SBP-0636457 (SB1-0636457) is a SMAC mimetic, and as an IAP antagonist. SBP-0636457 binds to the BIR-domains of the IAP proteins, with a Ki of 0.27 μM. SBP-0636457 can be used for the research of solid tumors and hematologic cancers[1][2].
SBP-0636457 (1-20 μM) demonstrates no cytotoxicity in BT474, BT549, MCF7, and MDA-MB-231 breast cancer cell lines up to a concentration of 20μM[1].SBP-0636457 (10-1000 nM; 20 h) is ef?cacious as TRAIL-sensitizing agents in MDA-MB-231 cells, with an EC50 of 9 nM[1]. | References | [1]. Finlay D, et, al. Small-molecule IAP antagonists sensitize cancer cells to TRAIL-induced apoptosis: roles of XIAP and cIAPs. Mol Cancer Ther. 2014 Jan; 13(1): 5-15. [2]. Finlay D, et, al. Inducing death in tumor cells: roles of the inhibitor of apoptosis proteins. F1000Res. 2017 Apr 27; 6:587. |
| Pyrrolo[2,1-b][1,3]oxazepine-7-carboxamide, octahydro-8,8-dimethyl-4-[[(2S)-2-(methylamino)-1-oxopropyl]amino]-5-oxo-N-[(1R)-1,2,3,4-tetrahydro-1-naphthalenyl]-, (4S,7S,9aS)- Preparation Products And Raw materials |
|